NABEL ELIZABETH G 4
4 · Moderna, Inc. · Filed May 8, 2026
Research Summary
AI-generated summary of this filing
Moderna (MRNA) Director Elizabeth Nabel Receives RSU Award
What Happened Elizabeth G. Nabel, a director of Moderna, was granted 8,371 restricted stock units (RSUs) on May 6, 2026. The award is reported as a derivative acquisition at $0.00 per share (code A — award/grant). These RSUs will convert one-for-one into common stock upon vesting.
Key Details
- Transaction date: 2026-05-06; Form 4 filed: 2026-05-08 (timely filing).
- Transaction type: Award/Grant (code A); quantity: 8,371 RSUs; reported price: $0.00.
- Derivative details: RSUs convert into common stock on a one-for-one basis (footnote F1).
- Vesting: The RSUs vest in full on the earlier of May 6, 2027 or Moderna’s next Annual Meeting of Shareholders, subject to continued service (footnote F2).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- No sale or exercise occurred—this is a compensation award subject to vesting, not an open-market purchase or sale.
Context Restricted stock units are a common form of equity compensation for executives and directors; they do not represent immediately tradable shares until they vest and convert. Because the award vests in the future and is subject to continued service, it should be viewed as compensation rather than an immediate market investment decision.
Insider Transaction Report
Form 4
Moderna, Inc.MRNA
NABEL ELIZABETH G
Director
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-05-06+8,371→ 8,371 total→ Common Stock (8,371 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
Signature
/s/ James Dillon, as Attorney-in-Fact|2026-05-08